Scholarlink

<p>Previous studies have indicated that PRDM16 suppresses apoptosis and ferroptosis, thereby mitigating the development of AKI triggered by ischemia, cisplatin, and sepsis. Nevertheless, the exact function and control mechanisms of PRDM16 in rhabdomyolysis-induced AKI are not fully understood. In this investigation, PRDM16 was found to inhibit ferrous myoglobin-induced pyroptosis in Boston University mouse proximal tubule (BUMPT) cells. At the molecular level, PRDM16 binds to the USP10 promoter, enhancing its expression and subsequently inhibiting the NLRP3-Caspase1-GSDMD and Caspase3-GSDME pathways. Rhabdomyolysis-induced AKI was alleviated in PRDM16 KI mice, whereas PRDM16 KO exacerbated the condition. Furthermore, PNPs-encapsulated formononetin significantly attenuated the progression of rhabdomyolysis-induced AKI. In conclusion, PRDM16 suppresses pyroptosis and ameliorates rhabdomyolysis-induced AKI by regulating the USP10/NLRP3-Caspase1-GSDMD and Caspase3-GSDME pathways. PNPs-encapsulated formononetin emerges as a promising therapeutic strategy.</p> Graphical Abstract <p>PRDM16 binds to the USP10 promoter, enhances its expression, and subsequently suppresses pyroptosis, thereby attenuating the progression of AKI caused by rhabdomyolysis.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月2日

查看全文
  • Bocheng Han,
  • Qiang Zheng,
  • Huiling Li,
  • Yongjun Wang,
  • Dongshan Zhang

摘要

Previous studies have indicated that PRDM16 suppresses apoptosis and ferroptosis, thereby mitigating the development of AKI triggered by ischemia, cisplatin, and sepsis. Nevertheless, the exact function and control mechanisms of PRDM16 in rhabdomyolysis-induced AKI are not fully understood. In this investigation, PRDM16 was found to inhibit ferrous myoglobin-induced pyroptosis in Boston University mouse proximal tubule (BUMPT) cells. At the molecular level, PRDM16 binds to the USP10 promoter, enhancing its expression and subsequently inhibiting the NLRP3-Caspase1-GSDMD and Caspase3-GSDME pathways. Rhabdomyolysis-induced AKI was alleviated in PRDM16 KI mice, whereas PRDM16 KO exacerbated the condition. Furthermore, PNPs-encapsulated formononetin significantly attenuated the progression of rhabdomyolysis-induced AKI. In conclusion, PRDM16 suppresses pyroptosis and ameliorates rhabdomyolysis-induced AKI by regulating the USP10/NLRP3-Caspase1-GSDMD and Caspase3-GSDME pathways. PNPs-encapsulated formononetin emerges as a promising therapeutic strategy.

Graphical Abstract

PRDM16 binds to the USP10 promoter, enhances its expression, and subsequently suppresses pyroptosis, thereby attenuating the progression of AKI caused by rhabdomyolysis.